-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QlS1rOjI0NoWyAvFc0x6KRqzEQIkWZ6+rh878HAkohq6oBMDQBCIF4eu5zqNa76T
 zCfNwxAqmr6pAjgZ8Pat6g==

<SEC-DOCUMENT>0000950123-11-001939.txt : 20110111
<SEC-HEADER>0000950123-11-001939.hdr.sgml : 20110111
<ACCEPTANCE-DATETIME>20110111111830
ACCESSION NUMBER:		0000950123-11-001939
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20110111
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110111
DATE AS OF CHANGE:		20110111

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IDEX CORP /DE/
		CENTRAL INDEX KEY:			0000832101
		STANDARD INDUSTRIAL CLASSIFICATION:	PUMPS & PUMPING EQUIPMENT [3561]
		IRS NUMBER:				363555336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-10235
		FILM NUMBER:		11521828

	BUSINESS ADDRESS:	
		STREET 1:		630 DUNDEE RD STE 400
		CITY:			NORTHBROOK
		STATE:			IL
		ZIP:			60062
		BUSINESS PHONE:		8474987070
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c62192e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B><FONT style="FONT-variant: SMALL-CAPS">UNITED STATES </FONT><BR>
<FONT style="FONT-variant: SMALL-CAPS">SECURITIES AND EXCHANGE COMMISSION </FONT></B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B><FONT style="FONT-variant: SMALL-CAPS">CURRENT REPORT</FONT><BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report: January&nbsp;11, 2011<BR>
(Date of earliest event reported)</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>IDEX CORPORATION</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B><BR>
(State of <BR>
Incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>1-10235</B><BR>
(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>36-3555336</B><BR>
(IRS Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1925 West Field Court, Suite&nbsp;200<BR>
Lake Forest, Illinois 60045-4824</B><BR>
(Address of principal executive offices, including zip code)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(847)&nbsp;498-7070</B><BR>
(Registrant&#146;s telephone number, including area code)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule&nbsp;425 under the Securities Act (17
CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR
240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT style="font-family: Wingdings">&#111;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">












<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 &#151; Other Events.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On January&nbsp;11, 2011, IDEX Corporation (the &#147;Company&#148;) issued a joint press release with
Microfluidics International Corporation (&#147;Microfluidics&#148;), announcing the Company&#146;s proposal to
acquire Microfluidics in a cash tender offer for $1.35 per share. A copy of the joint press
release announcing the proposal is attached as Exhibit&nbsp;99.1 to this Current Report on Form
8-K and is incorporated herein by reference.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Important additional information will be filed with the SEC and distributed to shareholders of
Microfluidics.</I></B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The tender offer for shares of Microfluidics common stock described in this Current Report on Form
8-K and the exhibit attached hereto has not yet been commenced. The description contained herein is
neither an offer to purchase nor a solicitation of an offer to sell shares of Microfluidics.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">At the time the tender offer is commenced, the Company and its wholly owned subsidiary, Nano Merger
Sub, Inc., intend to file with the SEC and mail to Microfluidics stockholders a Tender Offer
Statement on Schedule&nbsp;TO and related exhibits, including the offer to purchase, letter of
transmittal and other related tender offer documents, and Microfluidics intends to file with the
SEC and mail to its stockholders a Tender Offer Solicitation/Recommendation Statement on Schedule
14D-9 in connection with the transaction. These documents will contain important information about
the Company, Nano Merger Sub, Inc., Microfluidics and the terms and conditions of the tender offer.
Investors and security holders are urged to read each of these documents carefully when they are
available.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Investors and security holders will be able to obtain free copies of the Tender Offer Statement,
the Tender Offer Solicitation/Recommendation Statement and other documents to be filed with the SEC
by the Company, Nano Merger Sub, Inc. and Microfluidics through the web site maintained by the SEC
at www.sec.gov. In addition, investors and security holders will be able to obtain free copies of
these documents by contacting the Investor Relations departments of the Company or Microfluidics.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 &#151; Financial Statements and Exhibits.</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><I>(d)</I></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Exhibits</I></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" nowrap align="left">99.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Joint press release issued by IDEX Corporation and Microfluidics
International Corporation, dated January&nbsp;11, 2011</TD>
</TR>






</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>IDEX CORPORATION</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Frank J. Notaro
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Frank J. Notaro&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Vice President &#151; General Counsel and Secretary&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">January&nbsp;11, 2011
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD style="border-bottom: 1px solid #000000">&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Joint press release issued by IDEX Corporation and
Microfluidics International Corporation, dated January&nbsp;11,
2011</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c62192exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 6pt">Exhibit 99.1</div>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="c62192c6219201.gif" alt="(IDEX CORPORATION LOGO)">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="BOTTOM"><IMG src="c62192c6219202.gif" alt="(MICROFLUIDICS LOGO)"></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>IDEX Corporation Signs Agreement to Acquire Microfluidics<BR>
International Corporation</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#151;Microfluidics&#146; shareholders to be offered $1.35 per share in cash&#151;
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">&#151;Microfluidics to host conference call on January&nbsp;11, 2011 at 8:30 AM ET&#151;
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Lake Forest, IL and Newton, MA</B>&#151;January&nbsp;11, 2011&#151;IDEX Corporation (NYSE: IEX) today announced
that it has entered into a definitive merger agreement to acquire Microfluidics International
Corporation (OTC Bulletin Board: MFLU) for $1.35 per share, net to the seller in cash, and subject
to adjustment as provided in the merger agreement. The transaction is expected to close in the
first quarter of 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The $1.35 per share cash purchase price represents a premium of approximately 69% over
Microfluidics&#146; volume-weighted average share price during the 30 trading days ending January&nbsp;10,
2011, the last trading day prior to this announcement, and a 75% premium over Microfluidics&#146;
volume-weighted average share price during the 90 trading days ending January&nbsp;10, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Microfluidics is a global leader in the design and manufacture of laboratory and commercial
equipment used in the production of micro and nano scale materials for the pharmaceutical and
chemical markets. Microfluidics is the exclusive producer of the Microfluidizer<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> family
of high shear fluid processors for uniform particle size reduction, robust cell disruption and
nanoparticle creation. Microfluidics&#146; product and service offerings will enhance IDEX&#146;s micro
fluidics and micro particle technology position. Headquartered in Newton, MA, Microfluidics
achieved $16M in revenue in 2009. Microfluidics will operate as a stand-alone business within the
IDEX Fluid and Metering segment. Microfluidics is expected to be accretive to IDEX&#146;s earnings in
2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The merger agreement provides for a wholly-owned subsidiary of IDEX to commence a tender offer to
purchase all outstanding shares of Microfluidics. The Microfluidics Board of Directors unanimously
determined that the offer and the merger are fair to and in the best interests of Microfluidics and
its shareholders. The Board approved, adopted and declared advisable the merger agreement and the
transactions contemplated by the merger agreement, including the offer, and
recommended that holders of shares of Microfluidics common stock accept the offer and tender their
shares in the offer.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In connection with the acquisition, Global Strategic Partners, LLC (GSP), a wholly-owned subsidiary
of Celgene Corporation (NASDAQ: CELG), has agreed, subject to the same conditions as the offer, to
sell to IDEX the Microfluidics $5,000,000 debenture previously issued to GSP (which is convertible
for shares representing, after giving effect to such conversion, approximately 28% of the
outstanding shares of Microfluidics based on shares outstanding at December&nbsp;31, 2010) and to cancel
all outstanding warrants to purchase Microfluidics common stock held by GSP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In addition, Irwin Gruverman, the founder and a major shareholder of Microfluidics, as well as each
of Microfluidics&#146; directors and executive officers, have agreed to tender their shares in the
offer; these stockholders own shares representing approximately 16% of the outstanding shares of
Microfluidics at December&nbsp;31, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The merger agreement provides for a two-step transaction. The first step will be a cash tender
offer for all outstanding Microfluidics common stock, which is expected to commence in January
2011. In a second step merger, any untendered shares of Microfluidics common stock (other than
those of dissenting holders) will be converted into the right to receive the same price paid in the
offer. The tender offer and merger are subject to the satisfaction of customary closing conditions,
including successful tender of a majority of the outstanding shares of Microfluidics common stock.
There are no financing or regulatory conditions to the consummation of the transaction, nor is the
transaction subject to approval by the shareholders of IDEX.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Commenting on the transaction, IDEX Chairman and Chief Executive Officer Larry Kingsley stated, &#147;We
are thrilled that Microfluidics has decided to join the IDEX team. Microfluidics&#146; leading
technology in particle size reduction and nanoparticle creation adds enabling technology to one of
our key platforms supporting pharmaceutical research and production. Combining Microfluidics with
our Quadro and Fitzpatrick pharma platform will allow for significant growth opportunities across
the globe. We welcome the Microfluidics team to IDEX.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Microfluidics&#146; Chief Executive Officer Michael C. Ferrara stated, &#147;Microfluidics has completed a
significant transformation&#151; evolving into an innovative, efficient and financially stable
technology provider with a robust product line that continues to serve as the gold standard for
nanomaterials processing, particularly for pharmaceutical applications. As we look to the future,
we believe the full
potential of our technology can best be realized by a larger company with robust sourcing and
distribution channels and complementary lines of innovative products. We are confident that
IDEX&#151;known as a global leader in the fluidics field across multiple platforms&#151;is the ideal
partner for Microfluidics. We believe that this proposed acquisition best meets the evolving needs
of our global customers while also producing the value and liquidity that our shareholders deserve.
We look forward to working with IDEX to complete the transaction in the first quarter of 2011.&#148;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Latham &#038; Watkins LLP and Hodgson Russ LLP represented IDEX in the transaction. America&#146;s Growth
Capital, LLC served as the financial advisor to Microfluidics and provided a fairness opinion to
the Microfluidics Board of Directors. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as
legal counsel to Microfluidics.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About IDEX Corporation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">IDEX Corporation is an applied solutions company specializing in fluid and metering technologies,
health and science technologies, dispensing equipment, and fire, safety and other diversified
products built to its customers&#146; exacting specifications. Its products are sold in niche markets to
a wide range of industries throughout the world. IDEX shares are traded on the New York Stock
Exchange and Chicago Stock Exchange under the symbol &#147;IEX&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For further information on IDEX Corporation and its business units, visit the company&#146;s Web site at
www.idexcorp.com.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Microfluidics International Corporation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Microfluidics (OTCBB: MFLU) is the exclusive producer of Microfluidizer<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> high shear fluid
processors for uniform particle size reduction, robust cell disruption and bottom-up nanoparticle
creation. Used primarily by pharmaceutical, biotechnology, chemical, cosmetic, nutraceutical/food
and energy companies to research, develop and improve products with efficient processes, more than
3,000 Microfluidizer processors are installed at customer sites in 50 countries around the world.
The innovative Microfluidics Technology Center, located at the Company&#146;s headquarters outside
Boston, MA, is staffed by expert engineers with a wide range of nanotechnology and application
experience for Proof of Concept and Process Development services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">By producing smaller particle sizes and a more narrow distribution than other technologies, with
scaleup from lab to production guaranteed, Microfluidics International Corporation enables
companies to create tiny particles that achieve big results. To learn more, visit
www.microfluidicscorp.com.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Conference Call Information</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Michael C. Ferrara, President and Chief Executive Officer of Microfluidics, will host a conference
call and live audio webcast at 8:30 A.M. Eastern Time today, January&nbsp;11, 2011, to discuss the
proposed transaction. Participants are invited to attend the call by
http://www.microfluidicscorp.com/investors and clicking on the webcast visiting link, or by dialing
800-659-1966 (within the United States) or 1 617-614-2711 (outside the United States). The passcode
is 85948002.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A replay will be available for one week beginning approximately two hours after the live call. To
access the replay, dial 888-286-8010 (within the United States) or 1 617-801-6888 (outside the
United States). The relay passcode is 91668867.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Important additional information will be filed with the SEC and distributed to shareholders of
Microfluidics.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of
Microfluidics. The tender offer for shares of Microfluidics common stock described in this press
release has not yet been commenced.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">At the time the tender offer is commenced, IDEX and its wholly owned subsidiary, Nano Merger Sub,
Inc., intend to file with the SEC and mail to Microfluidics shareholders a Tender Offer Statement
on Schedule&nbsp;TO and related exhibits, including the offer to purchase, letter of transmittal and
other related tender offer documents, and Microfluidics intends to file with the SEC and mail to
its shareholders a Tender Offer Solicitation/Recommendation Statement on Schedule&nbsp;14D-9 in
connection with the transaction. These documents will contain important information about IDEX,
Nano Merger Sub, Inc., Microfluidics, the transaction and other related tender offer matters.
Investors and security holders are urged to read each of these documents carefully when they are
available.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Investors and security holders will be able to obtain free copies of the Tender Offer Statement,
the Tender Offer Solicitation/Recommendation Statement and other documents to be filed with the SEC
by IDEX, Nano Merger Sub, Inc. and Microfluidics through the web site maintained by the SEC at
www.sec.gov. In
addition, investors and security holders will be able to obtain free copies of these documents by
contacting the Investor Relations departments of IDEX or Microfluidics.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Contacts:</B><BR>
IDEX Corporation:<BR>
Heath Mitts<BR>
VP &#151; Corporate Finance<BR>
847-498-7070

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Microfluidics International Corporation:<BR>
Peter Byczko<BR>
Vice President of Finance and<BR>
Chief Accounting Officer<BR>
(617)&nbsp;969-5452, ext. 243

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Investor Relations Contact:<BR>
Kari Watson or Doug MacDougall<BR>
MacDougall Biomedical Communications<BR>
(781)&nbsp;235-3060

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c62192c6219201.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c62192c6219201.gif
M1TE&.#EACP`T`/?_`+.TM)_)X.7EY>WM[>+N]#,T-(2%A6.FS0!NM8J5F<WB
M[1R"O,/=ZN;Q]@!RN#N1PP,#`WNSU/7X^FIK:Q)[N/'R\:RQLEJCRZ7,XN+B
MXKO!Q,OA[.GJZM+2TBJ*P/S]_?K\_0!UN]/E[I&2DK/3Y`!PMO7V]@MTM4E*
M2KK5Y0!OL]C9V:K.XE)35)V>GI.9F\7&QNCQ]7)S<R,C))VDID&5Q0QYN*ZM
MK7IZ>D)#1(R,C**BHBLK*]75U0!ZON7JZSL\/&)D9:W1Y*;)W9F9F5M<7#2-
MP1L<'+W:Z>SU^-CH\?GZ^MW=W104%(R_VVJKT+V]O?#W^92=H76QTYK&WOCX
M^*6IJAE^NNWR];.XN9W(W^[P\*&LL-;8U_?Z^P!WO-/G\(6[V7Z`@<W-SDQ0
M4<G,S2R(O^_T]@UWM\G>ZB"#O,G)R;>WM\'$Q2F$N\[2U)?%WMW@X?+U]@%V
MN5.>RFUQ<@!JLMK?X`!UN-[M]`1UN-K<W+S8Y_+X^2&%OI[&W1IYMP)SMEY@
M80AYN2\Q,=SK\XN/D>/FYC**P(:(B9'"W?W__[F^OL;)RIB<G?C[_)"^V:FJ
MJ;W`P?___7&MT09XN,+"P@5UMS8W-\[C[K3/W__]_!)YMP]_O9G!V28H*2>%
MO3P_02&!N@!FKJNMKC]"0__\^X*VU0!VN'9\?@5RM`%PLR`@(`!LM`9QLR6(
MOV9H:"\O+Q<8&0!YO0!XO`!XO0![OM[L\P!YO/O[^_W__>KN[^;GZ.OS]YR<
MG$>8Q_S]_PAVMP!YOF]N;QR&P+^_O\3;Z);#W-'7UY+&W^?GYY+!VTV8QD:9
MR+"PL)W"V/;\_`!WN[FZNX_!VN?P\^+O]0A\O,C+S`\/#PP-#1`0$`)UN-?I
M[T`_/]OH\"6#NT"0P`EPL_K\^P!EL?#O[[O7Z+?7Y\[0T.+CXWVZV?+S\];I
M\DJ:R9;"V\C@Z\W@ZB<G)[#/X+[&RDY/3Q]\N86XUY:7EV9G9UA9671W=_KZ
M]XRZU1X>'P!ZO?_______R'Y!`$``/\`+`````"/`#0```C_`/T)'$BPH,&#
M"!,J7,BPH<.'$`W^BUB0#Y4`&#-JQ*B%2AY_[BYN'*F%P9F(XD20$#*RI<N7
M5(0<Q!)`RTN-BDA\D$AQX",WHU0('4I4:*M68$"X:56TJ=!+HB+T:BC'TP,;
M@1PXW>JT!!X'8,,Z:"638`QP=K@.736*$X.#$WOZRU2I5K^[>//V\^'@@;\T
MP;[H'7RW5HA6B-(L%(((@8-:LV81GGPWQ!<?>"-KCBS,`:BI`JL902"9\EX'
M"S(AC-N32@G3=WT@F.*O'0+,L/':<G"BK,$/$>PXP)U[<(@'"P2;]M'JB4`P
MB%[#WDU!]6JY_BXXR#UK#A)_[+87_]?M(%RYWT_LU+(U?O"L$.;V(6!ONM:J
M%-[HS8?-=\'WA*Q%U,L"(>06@A\2)'%%@>W=M9L?H`DDSA.D-3C8%YU0@\6"
M]%'VQ0(+.-#A9+:$<((Q"P4(40JWY>8`'9.4(YZ%_=C2"B4$A6%':33BY4`S
M`@4@'6Q??#$B826BH0E#*CX4P9"4"8.'%OY$T&*/M5!PBT`I!$)+>\3EY4,)
MZ0CT00TS]JB;B4LRV9,N:.:&81Z3@#.<FK+5XX\$1J0)FP,(E"#HH(*.TJ8_
MQ@1BEYH.AA#.H2GV),(@7\(6@A&FW&*#<CWR58,_D-AQ)))?@7,*%7"DJNHQ
M5)PTT`7[,?\:@BOQ/-1D0W"HD-N8M,&!`*-W?:B`&0Q::H8YDSQ4"`7%TAA"
M,!A`="M#!T`YV2SW^5-MF#3.8DT-VXP7`AU_*.+$N>B>.\4&!IWR:X\AZ,%"
M1-,JU(<'S4X6PBL2>($OL'CE:]IN@1(Z*`*KO%50'V;<V6`(ET1++T5\Z,$C
M90Y<X(\"E,(V"RU?T"+RR"2'3/+)*']1R\HLMUQ"#;H<Q((=18X<LFGQ2CQQ
M1,%Q2U@)BH!ZY60^H(*&#4@GK?323#?M=-+AZ'G0(\RXPC1E.<M5+T*+Q`E;
M+8.`X4\S?NK%%QV9I*WVVFRW[?;;;/>14!0;L*W%%Q<'&S%V6Q__Q(T-E>)L
MQ"0-+`A;"?-BI[A#+)0]BQXZ]]2W01A8.UD)M)D32-YZX:+'$)EL(/KHI)=N
M^NFHB^X.&(L<U(L[IHMP00G</JZPUA%5RQT>YE0Y-&6HX"'\\,07;_SQR`N/
MBAUT''0+(BH8CPHN2+X<,^X/1?&OI:_TL8G7'F\F_OCDCP]9^;640&5!A417
M/N=WS5(""7Q#9$PE\(M9P@6;*+$IP)D9CRWPP!4$5,(;!;F%!VA'H[XL`7L.
M"</O"".;H/VA%3[KD<B*,XM*3$,(&`BA"$4HA$<0)!,>*%M[5I$XBDQN("``
MGX<ZL0YM,1!@7_##`5!1G!<]1`'T4&%[_QQ@!`E([B%Y,-QR^O(!"6P/6#:*
M@`CJLJL2/"`%27@$"+:XQ9T,9`-!')6%$$"%(S)N%56,P,:"L2A@?0$-2EB$
M$02&)`?@P0\/R&,>$>$<@2`!$"40HX5"X($DN/`A3[`<81R0`J%EL$&RP9$_
MIA"KZ;Q'+`X8AR3-@081`;!&"%C&(1L2A5?042\A((8AR?9(`9;`#'(0"`-4
M$3@+S0(/WR%!)P69ER\X@'J64H,AI>40P`#3-#ZDQA4XU:,D*68@NNO1%XBA
M#T^X(@2\#)@UIF"#-E*F!&'8&4,@\2[3O"<9_C!'A=14HA.T4"`Q<(,G+92Q
M9Y0`FP8*QKP2:?\@"A"`F`S9Q"^$F!>PB8V2V1Q8"7IS$'=<89X-\L,EF$FB
M9R4N!DJDC&S4:*N&5&.9+GK`!W*!IE92QA9?:(4;&HD0=RR%HKFA1?Y0:0/?
M^.,8$S0.)Q#HD!>RH!4A"*I0ARK45M!&"<%P`%&7RM2Q7.$)$4((-0Z`AA(H
ME:E896HTMKI57]J`I3ZI`5"#RM6R1B.E!_"BFQAR"D"HX:UPC2M<Z=$[(;A5
MKGB5ZP)`\8MZ%.(A[YC"`_)*6,)2X+"'18,9W'$08WQC`6]%K&0/:P-1<*.G
MI&R`9C?+V<[N)`K5Z*QH1YN$9%$D%Z--;6IO48C6%D()42U($C;+6M?_VK80
M!#!B0UZXN-[Z]K?`)0AO@TO<XAI7(0'*A1>7:Y#6#>0#'UA$%0P"`MT:!!T=
MX,!!.-"!#/S&3-_UAUH)4H$>K&"\X@4O0]`[4H$\<"!+V$,/U,&07/B#-59H
M`7WM@8G^%J`%C!C(#OI+8![D8Q$&R`$Z!O("3*S`(#"8QQ%D(8LZT%<@;\`'
M*V31!!0\V!^/F$`!"(P)`[S7`"/&1`%*<8.!#"`?_)"%-@J0!083N``%F(`R
M"#(`%-QC)W7@`2:ZT0T5%V`-'$!!,<QDB%@<H0E'T,%`7`"$``MD"RV`PGT'
MTH("@,`?0"B`"XC`7PBT02`H@,<+$L#F!&C`_Q]M@(`8!&(!"!C"N0+.!C[8
M`(-$0&`"`@%`-EK@C#7X`AL\V((_X@"!((S9!1.`P`CVQ(]22"$!+P@%!)#A
MCQ6P@@=$@`$`@`"!,HBWOX[`M!@@,`^UX@`"3=@Q%Q(@!4(<@0AL'H`S('`.
M?U2A!=I(!`PL400($$$@9(``"@8B#PC`8,O^R(6!_2$`;!Q;(!+@Q[*K<(0Y
M'P0%3<C%&"!@`(.L`0*)($@0>-!I"."`(%`PMC\$S02"-$$0_M@#!"(QD`Y`
M(`M+6/&%_3&`)N"#X$UP`4%:P(KWCH$58FA"!PB"B7L0)!^LF&X0FO!A@>3@
M$Q^HP"<*@(T>"$0'K/\P`;1[D`U^Q[D1!"G")_S1A6R<^2!QSL<,9/";4@"A
M(`-X,`H*4!!U-('G8I@!06```0OXXP9-$`"#L\$!*4!@P0N/A3_DD0V3NY<?
M/!=O*62`CFP`8""\2#A!4+!LIM>8((G(1@6ZT`1&\*`.`FE!#@02%U)D8P_^
M,(0LM#L0%/S\!A#(00O(0`842((@\X!`V`O":!H<I`L0V$%!MM"$.;>`!V/V
MA0%BD0K[BD$;]O"%+W"0#4/X@Q`M,`@9NA'X;(R`"+X800Y00'@7',$$%<B&
ME`7""`B,82`FF(&4!<'N@D2\"K[01A4B;H)-?,+;<9'!#!Z(#Z+#%^S^P$'_
M$X8Q@?)/8.("6<$,(*!P@]39ZP79`03N4)!S9\$4,Y`%(6)!"&QDHPMYEPV$
MP`.?@`D*EP'98`\%L02L`&A%(("$0`BL``&.(!!8<`3#@`X]T`2`=G)',``#
MT0@0\'CP``L&,0\_-P&TQP1-MPO8X`Q\YW'+!@*?,`P$P0:\Y@^A$'L'\0.R
M``N"P`_D8!`CD`U2-Q!Q(`@<X`O9P`L%,0&RL`0K``%G)Q#^5FXFP`H&L`C0
M``T#<0Y-5Q"[=@W^``\=Z`]R@`D_YP^K-@.L``^LQF7+-F78\`/^<`1X1Q",
M]@*O9W'^P'90@`WTMV5G$&6+E@U.)Q#*P`_X5@&R_U"!!K$%A``$BU`&$.`+
M!F$%$&`)!-$-L;`$`$"%!"$)[.</5J`-3B@0'"`++;8&V;!D!<$+V6"#`\$!
M1U`$_J`,34`*!)$#^+8"V>`+8]`&8U`$,V!"2_`)J4`0PT`(`H%C!3$/G[`$
M!6=Y_L`&V#!T)K1EEOAFNT8#\B`/1#`#.5`!<(9N`'`#ZN@,T%`!I0`/NQ!M
MF#`#YD@0`M`$A#`&`W`.$E9OZO`)1R`-`W`'.I`-83<!GP`,`\$(V3!Q(P`!
MAW`0]P`!]J`,'!`)K``$((AXQR<0N]`$([`)W5`*<`<!4C>%B1AM\("+_N`"
MDA<'R@`%0'`$$R<-#>E>!?\``?@6@SL`#W:8"$T0E$U0`#@P72T9E-B0E-A`
M"'U0!S/@7726#;Q8$)8`#]G``_S0`O4F$,A0`-DP`_SP"9"X""APAJ8H"V_@
M#Q,0"N)P$.30`A#PAAA8CXD0"RHG$'<P`U;0"#1)$*0@<?X0"4>PE?[``3.@
M>0)A`-G0!#/0!//P82]0``.W`]H`B5NV!0*P"?ZP"P*0`9YIE`(Q``*`#I[I
MF0/P`7M0CP*Q"`*P8P9!#E#@#!TW$%4``\Y0#`/W`;P02P,A!QE@CAP0CPG1
M`0`@#4<8FH0G$%[`"UNP"\DI$%6`#BI7`;R@5DL@`-LH$!D``&PPFUL`@O8(
MFL,I=5SD69[!-9[FF9[JZ4+_T)[N^9[P&9_R.9_T69_V>9_XF9_ZN9_R&1``
!.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>c62192c6219202.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c62192c6219202.gif
M1TE&.#EA]@`J`/?_`(/&S?C__VIH:#DV-5A55HB'AR@E)GG"R6J[PZ;7VTE'
M2%>RO:_;XN7R\OGY^2>:J46KMMW;W+2SLQ25H\S*RV6WOO7__^GKZ3:DJ-/K
MZIS2U__Z_M+1T/K]^JRJJ]KK]KRZNHC)T^CT]>+AX9R:FL3"PO__^CNFLNSZ
M^_K[]83(SI7,U75R<_S\_.;EYK/;W923DO'Q\1F3GKO@Y][P\AT9&MSM[UVR
MNP"$D^[M[<#CY%FUPD.HKO7U]142$_SZ^?_]_/S__&*UM,WIZ]'0S];5U4NO
MNJ2CHO_\_U2MM]#.SOW__WQ[>P@&!@&)DL7DZ^GQ[`*+FO/Y]?S]__G[_LOD
MZ<GH\1D4%0"$C"V?J([)S0J0G@!^CNCFY?7Y^?S\^O#^_O_\^LCBY>OU]R`;
M'97.S>/O\?O_^B.9H0"%F!L6&-KP[9>5E8/"R`R+GP(``/3Q\M'J[?#Q[O/W
M^N/U^`\*#.CIYO'X^?S\^&YL;8K%S_GX^]_=W34R,5&RN.[LZ^SX]I".CE-/
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MJ-74U$5#0WEW>.7DY,?&QL'`P.KKZG^`?)B7E`\.#?___./CXPN(F=;6V,OJ
MZ-38U'#`Q,G)R-'HZ=#/SH7&QO+P\2`>'M3M[">CG6UN:?/W](S.TX[(R-/O
M\;_!OV1B8^SL[,7GX%&SK^SNZ4ZML8:#@]+1UC&CL2\M+J#0TC`Q+A<5%EFW
MN8V+B_W]_?___?_______R'Y!`$``/\`+`````#V`"H```C_`#<@P08D2(``
M)C8%.&/"A#\D2/SY$R%&QZ5W:P)(A.@O@(4`GSXI"K+AQYD49Y9(7,FRI<N7
M+/FUD,B/G[^:-V'BA,FSI\^?.F<"E0FT*$VC2'_^FU+08)`@_8!\"2/1@9@5
M"(P867!CU@(C$'8<>.%)HHD48;Z<X0<D[1>H28W:W+DSJ,VX>'O>75GW;EV=
M,O<>'2HXK^&5_YXZ#6)B2D1_=!(<N`$VK#<`;0[,2F(DR0)O9:JT,`%D2I`6
M2/AU`.*OW^&?=`NWK"G[->$6?F?+_FN7]F#`<_T*WFT;YC\309:<Z0#7WQU=
M*DYD\:,E%JXE3_F%V0#$#`-O&#`(_TE`@XJ_)5,V4+$PI7C1O;7=YY6)&[#A
MN?5_MLC/5^AOOO*U]`\02/3S10I?2(0",!ADX8T.-.#R0TN/F2!%`]QH($\6
M%3PQ10!!I')&`%2T%Z!=)P:($V\I#M6B8?\@\<47)GQ!X`?@R7//&A)A0YI`
M_%A`A7FM231'+&WPP$,"*M7X!6J/O0@@BU+*%1Q-\?&594O[W;2E;K/%--R+
M`[:00@</5;&#.?J((9%'9RSW9"IP^BA3$!+U<`\&$#!@7BJIM,!=E2[U1>A[
M5WJ)99A4OM3EBH0--MR8+?[S23\M..#/!Q7(,(LL$DWQ41!QGO%)*F&$$<0G
M#7W1P8@2,?\`09]WU)@6GBG&IM.A+7X9DZ))^<JK/_^LA400*!R0!0+KW*0>
M%4N@IU@_&W#'3Q#;`>&01(HD`,&22T05)Z^!+3KL?/[=-Y=M_/U:96*I.*>A
M-W28E<I40&`3!%L/36'>%`!'"9D98R20A3[<(`'$M;RV\`HJJ&3C3BOIGNN3
M*B.@,L(([CBL<30Y:(I7#]&,H`PR,50,DP/4=-))-!WWX$(VG;@0`WQD+A$&
M$E9`((,0#.ABPP:M8<-<$/A^Z!@0KBDR1`(A')#."W<`HHXY!U!!D&LKO3(*
M#"2$W0PEB/3`4@NLX4F4/RT,`L(Q1X2-R3'+J#)*'HPP,<HRN4G_E+9**DGT
M5.#1UK0$3H$CRI(#O"S""330V))',^Z`D@<+3/22C;MBOE0$$XRP4,`TJ@"U
M#";08-Z+)^$48(OHT\RTWUW8)><3$*SQ%"VQ4(D0PA9<:/.`$=XD0$L#&@G^
M!3\@YB[".\#<<$(]$!P@!@K^-"`/!+*TH"]+'/31A!I7U`"+`I,'L])^"[,]
MDRHE0*-`'\2HX8,QSVCBSB1O-.'#)-]85$V`@!W`>6EP-RD</PYGD\05AC=U
M<8`2!$`,'ZSB"CYX0SN608@FW,(1>4`$3;H$)I=H(A]-:((]1/$*H%!`$#7X
M8!ZBX0%#U*$.!@B$[/Q3.P8ZD"6XZ\GN_X[CCQF<(`II<((3HK`%&9S@`+I0
M!#;Z$:<IF,H$5/@``++@"C148`8T&(,B'+,!#?@!`"+PQ[8D$KXFK$(-:JB!
M(QQ!"DF4[B'[.99-6B`!`A"C!C500SZN<(O\Y4``UU`#,03`B__`1F6%4MPR
MYF&(*UB2#&2H0QXXZ$%R/"(1CLP)3RAA``N2@@TM%"5,7J@&&4;C&*2H`1GZ
M`(,)"0M82!G0!E:`AA.<8`).P`(6TA"%"9R@#%#8Q!FHT()/8&,.WG+%%N2A
M@4((#`D;$$$%,."A#J!-(H@8P`?)`$CRJ>$9I5B)PE@2@7:L(A^K`"0YR+$*
M!1PC!B`(!!M(`/\".X22)R3DR2U;,HUAJ&$5J^C#Y=IQA&P0H@ZK,``C1.B2
M@,*$#R2``0R.H`2S_40)!'!$/@R0AVR,X`AL8(,D>+''@<8E1F9`0!8.L((R
MA&`6&/@%#KB``S1X0QAXBL@:0I`%',C`&T.0R!G6<(D$O(`&1"-J`J3@S970
M0YSD<(0A'%$#<M3`!X^XP$98H@H2].$:9"`',8CAU7H>0Q41F$8)2I"+<;!D
M')U@!@<2P=>^.H,($7"`?^#`!R+L-1%$<`8R1.:/'/"AKWTE0B)&X%&)>*`6
MY+#?,TC0#$Q\PP4$@*@!'I&+'A2!`T3(13#VXQ]^Q&`0AG5&-!SP!VG_3",3
M%(C&A"32BKPF`A&(2(0SBI"+9C2"&"/-0R?@0`';2F,$BWM%!!#!`0X`5[B(
M988<)-*"8.2"",'EJS.`&UQG<(`/JOB'/V15#%:(XP55>$$9MKF%-`0/`>"`
MB!D.`,PLK*!T#1`#,+Q!X!58@F@OT`<`#N&0NW!`G#6P!P$(T`=`^N`9'M`4
M:E:2B)#6(!_$(,0PR'"%?"A`$^,X@@`>P0))0/<'?*`$)ESW"$8\HL:/P%L[
M1&%7TTI@$:$0`-X>(0!H9")3S"@%&T)QXR;GF!$%6,0T7&!9S,*1%(^`A@`\
M$(V'7H$8C$!%!+0L@%"`(`:#<0`1YB$``;!@_Q2>8`83A%R`3,"AL;P8Q3QL
M@>,;,\(6A.B#(U9!C))R8,^/,+-$@O&-KS$A#WUN<IF_,05DE&(?+!@RI&WL
M9`%@@@_J30<P?[$%5V1A%F5XP@P0@`8GI&$+"+!!`_B;A@<P8`Y4>`)XT,`#
M+93C#GMH#2TTHP/7U"<1I+A&/OK`"0_D`9"K((,`HM$251S!'K>0Y3,R@8D/
MUY,2GLB#,<A@B#P0@1]%R(,]#&"`M;I[K7.\!0$\P8\2M`,6AB"&(PPPQP@O
M0A72((0]#,'O.<YQK08@."D*@`Q^'*,6@'0$,=B=#T:,8!)U\`$Q;.$":?0A
MCK7PA3NXRUM-*"#:]O^`!C)*`(NN;M83K3B"`M;M"'*TN^829ZM7"QT-"=1B
MWZ0@@3]:L8B9W_S=^D;N`#R@"@\,8.+L/CC"X9V/22A!O=Z(PD[3P/4MU&,!
MU4S`$8TZBP.8@PL/T(`4;`"`>KCA`7J800,<TH]HT2$=/&#`8)!]#1_88Q\N
M.,8`+%P+3536'[R8A"/(9X\"]&`4<*S!B=W1CC?4H0;M2`0RYF&/OOO@?K<P
MQBU"+_HW-"(8T6`".3S_>=$WH09LF,8CB&&,S_L@]/<SQC6,D0\?7(,4B_"$
M)FJ!2:_>3X/+P+@:#,`"9$S#`!ZD)372+($!-,$8CF"$'3)!CCK<H@\DB('_
M-(:1C]KKWACHSWT^NEH#GA^C#[?P.QL<$(Y)W,\'Y0_]Z#]_BS<8HAD4\`CY
MH&SEUWKI9WY-,`P4H%X+,`$(@``[X#,[A0-9T`96P`!&$$Q;`$RN(`XH\`X5
M4%\0D`!SP!($,05@P`!9H`$M000#8`Q78`@%,`XNP`+$<`6$E@=\L!(]@`F&
M@$G&H`"-1`+VHP8G=DAUH$@"\%C/X`-I90"U(`B-,(54V`BD$`K!D`D*8$&S
MI`!4^`P$H`EL8`_11@Z&T`A22(6"4`L&0`[Y0`X"T`F40'SD=(:"0`J!,`(/
MM7R/$`TE8`BW<`4#``.IM!(.4`FUP'L&8`O!\'P^_R"(=L0&9+!^!C``53B%
M@O`,6]5^,P1+@-0'P8<)`P!/-3``:>B%5%@+[9`)FD`(9!!ML-`($S:+PS`,
M!#`,"L`)S*!>?O``*Y``":`!;0`/6;`%6!`%LU`(,\`#OZ!U3E`!M/`.?N`$
MO^`'EB`18Q`'+W`):^``K*$#OM@22B!.:@`+\T!EFD`*5T!BL"`!(L,+[1!'
M-6``3-`*_H`)JX!_"E`)2*B$R\`+9]5^@H`)$E`*!GF0Q]`,WQ`#)#!X'S8)
M'G`,!GD,E=`)^U`#T19B'J`)$UD*E7`*F)4/CM`.,49\7Z4`'B`!S8`(R!!:
MA-:'?_B(@UB(58&(O$<,S?\W#8;PB*0`"G!0`(E$!J3`!*50D`>I":+P#(M'
M4J\T`.34!T>`#$Q@`/%$CYH@`<<@D:60E1X``B.0"9.`D?54`&%3EF'C"YBP
M"-*07OYP`SBP!1BP`'IP"=R0`$907\^H"P;#=<5P">!PEVEP`Y:P3$,0`CN0
M!?*0`&-@`OT`CF70$N&D;.;8"?XP`@)@`!CI"+8P"/Y`!3!088%$`-,@$9A`
M/O7$CP)0!U\F`!$0#@/0=[!0`"/@`+19F[79`JU0`/:`D3Y0`+9)F_P0"!94
M`X8P#YY@FWOP`T1`"")%#!LTAUQ5!X1PG(+U"L,@6BS@`B502H+(!B.W.,-W
M"R/_E9W/9PQJ`'RJL`_B60."H`FTN0>V^0W#(%*C%7BQ5`-]``I2297DH``@
M\)N_V0(E$);Y<)ZBLP\%D*`%@*#[<`2YX`#J-0M<H$1;\``G,`L)H`LA(`-8
M,`$5H`$GP`4..`,JX`9IP`,SL"D'4`]HD`1:P(U>D`J-B0:/Z0_8`$[)YG<%
ML#D.4`I-2$Y+YP_;0`CKIP;DX'@2080%ZI\YD`>JN4@1,(Y]-P"!\)TPT0.Z
M.8D^(`HO(9SQ]'?!UA(1,`G(Y9S+``+$IP9U,`E>T#6"4`<CQ0C:N9/=68@1
M<8BU<`O+QW$QF0\]"0>!4'MJ0`"9\!)$X$=Q^DKWF9_[_[D*Y-`(TN`3%!"/
M/M!^?3```T`*I("IFDH*M<`)B,"`6.`*P<0%7)`&)[`",[`"&$"-)R`#7)`%
M,P`,:)`&$Z`!*?`$%:`-3N`'4[42\:(#Q5"C7(,(I"">]C`/T.4/%_`(LO1&
MME`"H0`+ZU<#C0`"*^$+IJD`E/`'J;F:42I.5]`'@.</K`$14?$86-IR]K,/
M-!$E@8"#YE,`IN`/RX,--N$,A&``7_:<Q+<*THEF#A$,UWD%CL`"7?"'@7A*
M(S<3=SJ'BF@+70`)AE![`[`(/RF>9$``(&`34]`/)G"CO!!2/B!13?F4DF`'
MG&``;]@(H^DWN,,^V(`-R"`)"O]@"`/';CJ+F8_H`TWP#$>@7CO@H14@#_50
M#/8U`=Y0"!I0#%J7!FX@!'$@H4[`"G$0!].H#3?`#19P'DN`!,CQ`N;`@F,5
M3H%HCLMJ`KWP#.53`\\0:/,448'0!5SC"Y9D8IH0#ZFY"H[`FN'0!S!8G/'0
M$^A0`/@02,;@KFKT%!(AG.4C@US#$GQ`"/2T2"7YBM*Y79_`K,-P#5^&L!3K
MN0/@"_;8$IGP##<)N@;0=\!G"@5P>8]*"2\1#HWP5:,5"8*'D7V0LM7`K^3P
M#.SP$Z8``KX``];`!M:0O,>[#P1`!IIU"DN!`"<P`R@@`C,``"?P"VEP5&+P
M.UQW`O?_H`'UP`7%D*$(H$0+\`1!=1YJ!`@:8`1Z)Q%$LPL#H)J3*1']@`K)
M@%#S5'/T]*C?D#O^X`NKP'LGIK?7P+<"@`KA@`\);``"(`VO\`H74,$6;`=R
M@`O[<+CEI[BD<@:-^WDV9W'!4,'4$`S!``FU"V*3<+FK<`V$L%T@?`'7&5&J
M:PRK@`_5T`T4;,*H<`2D@'_,UP7L4+%^*@FNJVRE>`IV0,$H/,&]$$L1]0BX
M.WC+)@E=T+L(A0^+\`HE;,$5;`?N@`Y2(`>1H`QHC,:1D`W9$`V=(`HB96(P
M<!PJP`H,H!%3(`(ZX`W%@`.N<`\,,'8WH`.S4%_R$`<J\`M8_V`."6`>N$-`
MX2(,!X``;C)6+IC`R;JL;.-TLN2\F.0#%VM7CU&:<'2$J:D&?<L'B)"G9$`,
M]J``M1C+@B`(P_`,\X`,@6`(@>0#BIL:=X$)7"5+ICC+M3C+-UL_9-`.$3"'
MSBN==C43!/NDV;F=M]#*`U"+C6"+!+"&F!F#\P`'F<"O5_"G^W`%1DH,I+#-
MM$S+!/`,Q."\!@`-75`*L:0&^1D,!6`(<>0(M3`,["S+"B``N+4/A$``A'#0
M"$T(DS`)ST!.5Z``HG`<+\`*WC!WV[(&XB`#3G`"%9`%41`%!P`.]8`#$]`&
M3V`$7/`+!P`%V(`$`=`"JJ(2#"`/;?]@!H-!!,F6#\E*F2OA`O/@"#[@")@4
M2(00`><QRN:TCYYPRHLT",E7`^5#2#<TU5/]!H+0"6SP@ZW4RP\A$29'/N0T
MU;<@UK)4!\10`'\P?)CDS%W]!P7+?"-0!()@2>0SUF(=?V5M"!ZP`2#`K^=)
M`N/P?FTKU75P#3<4?V$]`*/0=*3PE(#M`:10!Y]\V'9]0V]@`*.@"=?I051-
MU4%-!CX`T3%B`Q5P`LT2!H%S"`?@M&Z@#:\6`N#(!2,8`@\0J[&0`B(2`%^0
M"D&`!%2P10G@!6HC$41@#V_P!HX0"M#U%*Y!`<]0V-=P#4W0!YA@-LUQ"BG4
M!*0@`7]0>?[_0PCA$`/'@*C1'=VC=]YU\`;#,`*B0`S2_0:<0!-!,$7]H`PP
M$$OWLWNZ%]W[/5+M\`W\T`MGE=Z"L%VN80<*T#^K(`#=,`[-(`CDX`.'[7O>
M9PPW5`/X(`"<J0FKT#^&``,YL`P%,`#Y6-[H5]Z[MPJ&P`2;0P(V9-:!X``1
M$`I]0`X67@>B=PVCYWW^E]FAA>-CS=]VK7LX/@D@H%Y3H`=9\`(=T`]3$#@T
ML`/UE08X`'=-RP6S,`-&X`91D`0TX`]Q`M.;8`)(8`E^<`*@DA(KD0N"8`#G
M(PI=X`]/X1`7L`_/@`\#T`>&P`*#<*,-(1%'@`^&@`^$``ERD`S$_V`(0\D!
M_H`'('`."H"IEXJIDCX`AO`(77`$=Z[GUB`1;]$0-QH)UD`(FTKIDR[IC3`/
M%,`:$C`,`X`/!G`.]>H0\=`.!H`/I%`-G&D*QP#I>6[JIBX(I\`!>.`/D,"&
M!M`(1[!=J'`*!+"I?7#JEWJIC;`/N2`1O=`(^(`/"B`)#L$'UN#JDR[MEMX(
MFE`"+/#JXT[IIL[MB]`#_Z`2ER`/-_`.YP$BYLH`]<!UOP`!*\!?7+"T(ST!
M!X`+8/X%&S`:':$%/'``@`#F[.L//9`(%,`+].`"N[4281`,1:`$J!4.D1`O
M+1$,X5#R@S`.+8`*O!`.'#`"]2KQ<<T!X?]`!#2_"S9O\[S`!S_0!;L0#KS`
M"W%>)"WA"=,E\S+/\B5?7;E@!U316!VO!+P0`6OT!1&P\D1`61)A"G%]\S9/
M!$J@!#8_"'_`-7#``3_?#:LE$7]0]-4U\X8E\T0@]KGC#M\5#L[@3Q+A"8/`
M]7R_"[R0"YX@!\O0\U]/\X9?7:B56G]`+%\[!NGP`%J`)E/P!7B`!+@P"ZX6
M!7Z`%6[`!0!`"V@0JPF`#O[0`4!RHVLP*X5`!4!P!JP!+0&P!`<!!M7;`+9O
M^R(`!A]Q$!XA`K??`+Z/`KP/!F.0^\/O^PTP!F#@$0=A`<[__,X/!G2``A_Q
M$6#P^[^?^[O/^\W_O_U@@/S4[_P>`?RXO_L6\/UFT`#4[Q'0W_[G/P:V+_S-
M7_LB$/X6(/O<S_OG+P+I#Q`H+`0@B,),`Q$"+2QD.#``0Q0HP"PD2+'B0(<6
MP/Q#TL+?.B/R+OGS%P9//VQEBD6)P@H8`AE;TE7)PH5'K`[^^&U`TL]?@P,8
M5"#Q!\0$/VP=EC0HTT8%`!5/`4R%&E5JU*E7J4+-JI6JU:I@JWZUBI7K6+1Z
MNDI5F[7K6+-JQ:Z5&A9K7;-WQ:K0@S?$U:>`ZZ(]F_>L4[Q7];1IDX#.OPTM
M@"AB@"')AR7]@O`S`0Z`$3]:7@#;,8N!%000VASZA`0(G@W^[J0SAV`-_S9_
M4Z8$"6*BGPT$1A8,)U[<^''DR94O9][<^7/HT:5/=^[GQ@T_?A9@EZ?GPS\@
M`8)@FP,@"X)U_5*Y=B#"AHT&@$30H`'HCID/#:1T:-%B?(L$3O#C$LZP(<@U
M$TSPHIPAXH@C`P@CE'!""BNT\$(,,]1P0PX[]/!#$#6TQ)(,&K1D"&YH\.*?
MHUKPB88V,$!@"'],`((D''W*$<<E^",*#`T@@&"&.3H*+X`I7+L11R:;=/))
M**.4<DHJJ[3R2BRSU'++*$WXYPQ^@``"-S/:.$&?%Z0@J1]^EEBB!9Z`V("?
M,\[H()4UP5%!P!=RFJ*_)7A;0C>2EG"-2T035?]T448;150WE+#I!PE*!_TG
M@#/"H#1!0&CC08-RYC#A23%-P&:333H0X1(ALF!%!R`V"6.*#FKE+`@DD5AB
M)TH=]?578(,5MLE^PC#ADR!\VA6(2S_Y1#<\PO!GC!<6J">)>VP(PI]>W?3'
M)R2PD>*2`T[`0)QRJ)CB!W:IP.,'8W%-<E>>B!KV7GSSU=?)8H]-UI]E_YF"
M']Y:2*&#*?S9H`H];N`!`F^`F<$&,\PXQ`P:K&#@@"1.2.*`!$0@Z8<4\.`O
MB"^^"&+0A`&>8LE]8Y9YYD1UP^9F;"C5=0K(I@B@GSH[H((*GZB(I8TD_-`'
M@3:TT$(=+4(X(#@(;KBD!Y<UIZ#"3GYR(WB)HH#HQ\W,>.OG;+335GMMMMMV
M^VVXXY9[;KKKMOMNM_E)F.P__0OBGQ^H$`^(((:F8N4`2*)"#'7@P0"#>DZH
M!P,($-!@#;#]"0!L;S?@:0.Q-]V$'R1W^^2,!%-7?7766W?]==ACEWUVVFNW
M_7;<8<=MBC,($OR,3S;Y9WCBBS?^>.235WYYYIMW_GGHHY=^>NJKMS[Z@```
!.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
